Philips publishes Q3 2026 results webcast transcript
PHG•Philips reaffirmed its 2026 outlook, with comparable sales growth projected at 3%-4.5% and adjusted EBITA margin at 13.5%-14%. Quarterly equipment order intake rose 8%, while a Respironics agreement in principle prompted a €288 million provision.
1. Outlook reaffirmed
At its November 3 third-quarter results call, Philips reaffirmed full-year comparable sales growth guidance of 3%-4.5% and adjusted EBITA margin guidance of 13.5%-14%. Quarterly equipment order intake rose 8%, and the adjusted EBITA margin increased 70 basis points to 13%.
2. Provision and sales outlook
An agreement in principle with the US Justice Department concerning Respironics triggered a €288 million provision, with payment expected in the first quarter of 2027. Management raised Personal Health’s full-year sales growth outlook to the lower end of high single digits, citing broad-based demand and market-share gains.
